Werngard Czechtizky obtained her PhD at ETH Zürich. After a postdoctoral stay at Harvard University, she worked on GPCR lead generation in a global Chemical Biology platform at Aventis. At Sanofi, from 2005, she moved into a parallel synthesis team working in the fields of CNS and CV diseases. In 2010, she became leader of a Medicinal Chemistry section working on Diabetes programs. In 2014, she was appointed Head of Chemistry at Sanofi R&D Germany, with therapeutic focus on Diabetes, pain and inflammatory indications. Since 2017, she is Head of Medicinal Chemistry, Respiratory & Immunology, at AstraZeneca in Sweden.

Presentation Title: The Right Synthetic Modality for the Right Biological Target

Abstract: Overview of AZ activities re: new modalities

What to use when - organization and criteria

How can CROs and academic partners be involved and contribute?

Covid - What new technologies have we implemented and what is here to stay?

View company profile